Floatz logo

BMS-986378

Childhood Neoplasm

Dana-Farber Cancer InstitutePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Childhood Neoplasm cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
City of Hope Medical Center
Phase 2/3BBB
FILGRASTIM
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2/3BBB
Carboplatin
Seoul National University Hospital
Phase 2/3BBB
Irinotecan
EpicentRx, Inc.
Phase 2BBB

View all 50 →

Same molecule, other indications

BMS-986378 is also rated in:

brain neoplasmDormant
CC
Indicative ·
47 / 100
View asset →
lymphomaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →